Microsatellite Stable
9 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer (NCT04119830) | Roswell Park Cancer Institute | 2022-02-01 |
| Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer (NCT05160727) | Zhejiang Cancer Hospital | 2021-10-01 |
| Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (NCT04262687) | Federation Francophone de Cancerologie Digestive | 2021-04-06 |
| Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer (NCT04194359) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-02-04 |
| Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NCT03983993) | Emory University | 2019-10-15 |
| Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer (NCT03396926) | University of California, San Francisco | 2018-04-18 |
Track Microsatellite Stable automatically
Every clearance here is in the API, with alerts when new ones post.